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Background:  Meningococcal  disease  remains  an  important  cause  of  morbidity  and  mortality  worldwide.
The ﬁrst  broadly  effective  vaccine  against  group  B  disease  (which  causes  considerable  meningococcal
disease  in  Europe,  the  Americas  and  Australasia)  was licensed  in  the  EU  in  January  2013;  our objective
was to  estimate  the  potential  impact  of  introducing  such  a vaccine  in  England.
Methods:  We  developed  two  models  to  estimate  the impact  of introducing  a new  ‘MenB’  vaccine.  The
cohort model  assumes  the  vaccine  protects  against  disease  only;  the  transmission  dynamic  model  also
allows the  vaccine  to  protect  against  carriage  (accounting  for herd  effects).  We  used  these,  and  economic
models,  to estimate  the  case  reduction  and  cost-effectiveness  of  a number  of  different  vaccine  strategies.
Results:  We  estimate  27%  of  meningococcal  disease  cases  could  be prevented  over  the  lifetime  of  an
English birth  cohort  by vaccinating  infants  at  2,3,4  and  12  months  of  age  with  a vaccine  that  prevents
disease  only;  this  strategy  could  be  cost-effective  at £9 per vaccine  dose.  Substantial  reductions  in disease
(71%) can  be  produced  after  10  years  by  routinely  vaccinating  infants  in  combination  with  a  large-scale
catch-up  campaign,  using  a vaccine  which  protects  against  carriage  as  well  as  disease;  this  could  be
cost-effective  at  £17  per  vaccine  dose.
Conclusions:  New  ‘MenB’  vaccines  could  substantially  reduce  disease  in  England  and  be  cost-effective  if
competitively  priced,  particularly  if  the  vaccines  can  prevent  carriage  as  well  as disease.  These results
are relevant  to  other  countries,  with  a similar  epidemiology  to  England,  considering  the  introduction  of
a  new  ‘MenB’  vaccine.
© 2013 Elsevier Ltd. 
1. Introduction
Meningococcal disease is a leading infectious cause of death
in young children in the UK [1] and remains an important cause
of morbidity and mortality worldwide, despite improvements in
critical care and the availability of vaccines against some capsular
groups. Globally ﬁve capsular groups cause most disease (A, B, C, W,
Y though X is increasing) and B and C are dominant outside Africa
and Asia [2]. The key to reducing incidence is prevention through
vaccination, because early signs of the disease can be non-distinct,
Abbreviations: MCC, meningococcal serogroup C conjugate; MenB, capsular
group B meningococci; QALYs, quality adjusted life years.
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the infection can progress rapidly, and can be fatal in 5–10% of cases
even if treatment is initiated early [3].
Effective vaccines are available against capsular groups A, C, W
and Y. The meningococcal serogroup C conjugate (MCC) vaccine
was  ﬁrst introduced in the UK in 1999 [4] and subsequently by
several other European countries, Australia and Canada [2]. MCC
vaccination achieved high uptake rates, and has led to a consid-
erable reduction in group C disease [5] due both to high vaccine
effectiveness and protection against carriage, interrupting trans-
mission and generating herd immunity [6]. Until recently there
was  no broadly effective vaccine against capsular group B (MenB)
the most common cause of meningococcal disease in the UK and
Europe [7] (MenB disease accounted for 89% of cases in England
and Wales in 2009/10 [8]). Progress towards a MenB vaccine has
been hindered because the serogroup B capsule shares homologous
structures with human neural tissue, resulting in the polysaccha-
ride being poorly immunogenic in people and concerns about a
MenB capsular-based vaccine inducing auto-immunity [9]. New
vaccines with the capacity to protect against MenB, based on pro-
tein antigens, are in advanced stages of development [10,11] and
one, Bexsero, was granted an EU license in January 2013. Policy
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makers are now faced with decisions about if, and how, to introduce
the vaccine.
To help inform policy decisions we developed mathematical and
economic models to predict the potential impact of introducing a
new vaccine in England, with the capacity to protect against MenB
disease (henceforth referred to as a ‘MenB’ vaccine).
2. Methods
2.1. Model structures
It is unknown whether the new meningococcal vaccines will
reduce carriage. Consequently, we developed two models (using
Berkley Madonna software [12]) to assess the potential impact of
these vaccines: a cohort model that assumes the vaccine prevents
disease only, and a transmission dynamic model that also allows
the vaccine to prevent carriage [13,14].
2.1.1. Details common to both models
The model populations are stratiﬁed into 100 single year of age
classes. Incidence rates include all capsular groups of meningo-
coccal disease because the new vaccines are not group speciﬁc.
Following disease, individuals may  survive with or without seque-
lae, or die. Survivors with sequelae are assumed to have a reduced
quality of life and fatal cases lose the average life expectancy for the
age at which they die. Individuals may  die due to causes other than
meningococcal disease; published mortality rates were adjusted to
remove deaths due to meningococcal disease as these are explic-
itly modelled. Vaccinated individuals have a reduced risk of disease.
Immunity from vaccination wanes over time, and individuals then
have the same risks of infection as unvaccinated individuals. For
each vaccination scenario the model results were compared to the
situation without vaccination. Models were run for 100 years (time
horizon) to capture the full beneﬁts of vaccination and effects of
invasive disease over the lifetimes of individuals.
2.1.2. Cohort model speciﬁc details
The cohort model was constructed using a Markov model, with
monthly time steps. Individuals are born into a susceptible non-
vaccinated state (Fig. 1). Meningococcal disease cases arise by
multiplying the age-speciﬁc probability of disease (in a given inter-
val) by the population. We  assumed individuals only have disease
once and are removed from the susceptible pool (instances of
repeat invasive disease are rare and are associated with individ-
uals with immune deﬁciencies and anatomical defects [15]). Years
of life are weighted by the age-speciﬁc quality of life. The cohort
sizes were based upon population ﬁgures for 2008.
2.1.3. Transmission dynamic model speciﬁc details
Individuals can have multiple episodes of asymptomatic car-
riage of meningococci in their lifetimes [16,17], therefore we  used
a Susceptible-Infected-Susceptible (SIS) model, with a daily time
step, to represent the transmission dynamics of carriage in the pop-
ulation (Fig. 1). Individuals are born susceptible. They may  then
become carriers of a meningococcal strain (vaccine preventable or
non-vaccine preventable), from which they recover and return to
the susceptible state. We  did not consider co-infection in the model
because current evidence suggest carriage of multiple meningococ-
cal strains is rare [18,19]. Cases of invasive disease are not explicitly
included, but are generated from the number of new carriers aris-
ing over time (see Supplementary Material) using an age-speciﬁc
case: carrier ratio. This ratio captures changes in disease risk given
carriage acquisition across ages, which could be due to a number
of factors including maturation of the immune system, physical
changes in the pharynx, exposure to other pathogens and immu-
nity following meningococcal carriage. Vaccinated individuals with
vaccine induced immunity can have a reduced risk of becoming a
carrier in addition to a reduced risk of disease.
2.2. Model parameters
Data sources used to estimate the parameters in the models, are
summarised below and in Table 1 with further details provided in
the Supplementary Material.
We  used carriage prevalence estimates from a recent system-
atic review [20], with contact patterns estimated using a simple
preferential mixing structure and recently published survey data
on self-reported contacts [21]. Disease incidence naturally ﬂuctu-
ates over time; incidence peaked in the late 1990s and has declined
since then. We  therefore based disease incidence and case fatality
upon hospital admissions from 2004/05–2005/06 to represent cur-
rent low incidence. Data from 1997/98–2005/06 (adjusting for the
decline in incidence due to MCC), which includes peak incidence
years, were used to generate a ‘higher’ incidence comparator. We
assumed all meningococcal disease cases were hospitalised and
estimated those requiring augmented care from hospital admis-
sions (1998/99–2005/06). We included published costs for time in
hospital including augmented care [22], and all survivors of disease
were assumed to have a hearing test and a follow-up review in line
with recent NICE guidelines [23]. The proportion of survivors with
minor and major sequelae following disease was estimated from
a recent systematic review of sequelae following bacterial menin-
gitis [24]. Those with sequelae were assumed to have a reduced
quality of life (0.2 utility reduction [25–27]) compared to suscep-
tible individuals, and survivors of disease without sequelae [28].
Long term costs of supporting those with mild and severe seque-
lae were estimated at £500 and £10,000 per year per individual
respectively. For public health management we included costs of
chemoprophylaxis (rifampicin for 3 adults and 2 children [29]) and
staff time associated with contact tracing. Costs of outbreak control
were not included.
Several vaccination strategies were considered (Table 2). Vac-
cination uptake for routine vaccination was  assumed to equate to
MCC  in infants, and for catch-up cohorts, match the MCC  catch-
up programme [30]. Vaccine administration costs [31–34] were
included separately from the cost of the vaccine itself, and were
greater if given outside of current schedules. The full charac-
teristics of the new meningococcal protein vaccines are not yet
known; assumptions regarding vaccine effectiveness and duration
of protection were based on data from trials, other meningococcal
vaccines, such as the MCC  or Outer Membrane Vesicle vaccines,
and expert opinion. Data from trials of Bexsero have indicated,
however, that the vaccine is immunogenic in infants [35], and ado-
lescents [36], that responses are evident after two doses of the
vaccine in infancy [37] and that it is possible to boost an individ-
ual’s response [35]. Early genotypic estimates of strain coverage
suggested 100% strain coverage was possible [38] however recent
phenotypic approaches suggest strain coverage in England may  be
73% (95% CI 57–87%), though these results are based on a method
which may  underestimate coverage [39]. In the base case model the
vaccine was assumed to protect against all meningococcal strains.
We included costs, but not quality of life losses, for adverse vaccine
events. We  assumed the vaccine cost £40 per vaccine dose in the
base case, but varied this widely in the sensitivity analysis.
2.3. Scenario and sensitivity analysis
The cohort model was  probabilistic, with distributions around
the parameters reﬂecting uncertainty (Table 1). Where probabilis-
tic analysis was not possible or appropriate (e.g. vaccine price will
be ﬁxed, but at a level currently unknown) we ran scenario analyses.
Cost-effectiveness ratios from probabilistic results were calculated
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Table  1
Base case parameters used in the models.
Parameter  Base  case  Distributiona References
Epidemiological  parameters
Carriage  prevalence  Variable  by  age  NA  [20,21,55]
Disease  incidence  (per  100,000)b 3.17  (variable  by  age)  Normal  (variable  by  age)  [56–60] b
Case  fatality  rate  (proportion)  0.04  (variable  by  age)  Beta  (variable  by  age) b
Years  of  life  lost  Variable  by  age  and  model  year  Scenario  variation c
Natural  mortality  rates  Variable  by  age  and  model  year  Scenario  variation  [56–60] c
Population  Variable  by  age NA d
Acute  treatment  parameters
Proportion  of  patients  requiring  ambulance  transfer  to  hospital  0.48  Beta  (261.48;  279.52) e
Hospitalisation  rate  (percentage) 100.0  Not  varied  Assumed
Length  of  stay  in  hospital  (days) 9.7  (variable  by  age) Normal  (variable  by  age) b
Proportion  who require  HDU  0.10  (variable  by  age)  Beta  (variable  by  age) b
Proportion  who require  ITU  0.14  (variable  by  age)  Beta  (variable  by  age) b
Length  of  stay  in  HDU  (days)  2.7  (variable  by  age)  Gamma (variable  by  age) b
Length  of  stay  in  ITU  (days)  4.9  (variable  by  age)  Gamma (variable  by  age) b
Long-term  effects  of  meningococcal  disease
Proportion  of  survivors  with  minor  sequelae 0.02  Beta  (1.94;  82.29) [24]
Proportion  of  survivors  with  major  sequelae 0.07  (variable  by  age) Beta  (52.41;  665.54) [24] f
QALY  utilities
QALY  utility  for  susceptibles  and  survivors  of  MD without
sequelae
0.86 (variable  by  age)  Scenario  variation  (variable  by  age)  [28]
QALY  loss  for  survivors  with  sequelae  0.20  Beta  (1.22;  4.89)  Assumed,  based
upon  [25–27]
Vaccination  parameters
Vaccination  coverage  –  routine  immunisation  (%)  91.00  Scenario  variation  (range  85–91%)  [61]
Vaccination  coverage  –  1–17  years  catch-up  (%) Variable  by  age  Scenario  variation  (variable  by  age)  [30]
Effective  vaccine  efﬁcacy 0.75  Scenario  variation  (range  0–0.90) Assumed
Rate  of  mild  reactions  (number  of  vaccine  doses  resulting  in  1
reaction)
1471.00  Gamma (5.9;  249.5)  [62,63]
Rate  of  anaphylactoid  reactions  (number  of  vaccine  doses
resulting  in  1  reaction)
719,790.00  Normal  (719,790;  112,140)  [62,63]
Cost  of  treatment
Cost  of  ambulance  transfer  to  hospital  (£)  169.23  Gamma (53.66;  3.15)  [22] e
Cost  per  spell  in  hospital,  (£)  2715.93  Gamma (8.03;  338.14)  [22]
Cost  per  HDU  day,  neonatal  (≤28  days)  (£)  759.31  Gamma (15.23;  49.84)  [22]
Cost  per  HDU  day,  paediatric  (29  days  to  ≤18  years)  (£)  922.38  Gamma (4.76;  193.82)  [22]
Cost  per  ITU  day,  neonatal  (<29  days)  (£) 1081.31  Gamma (13.74;  78.71)  [22]
Cost  per  ITU  day,  paediatric  29  days  to  ≤18  years  (£) 2056.20  Gamma (26.31;  78.15) [22]
Cost  per  critical  care  day,  adult  (19≥  years)(£)  1149.11  Gamma (12.95;  88.73)  [22]
Cost  of  follow-up  appointment,  paediatric  (≤18  years)(£)  221.82  Gamma (2.50;  88.90)  [22]
Cost  of  follow-up  appointment,  adult  (19≥  years)(£)  292.91  Gamma (7.36;  39.81)  [22]
Cost  of  hearing  assessment  57.56  Gamma (6.63;  8.69)  [22]
Public  health  response
Cost  of  public  health  response  to  a  case,  excluding  vaccine  costs
(£)
68.00 Gamma (27.5;  2.5)  [29] g
Long-term  effects  of  meningococcal  disease
Cost  of  support/care  for  those  with  mild  sequelae  (annual,  £)  500.00  Gamma (6.25;  80.00)  Assumed
Cost  of  support/care  for  those  with  severe  sequelae  (annual,  £)  10,000.00  Gamma (1.28;  7832.44)  Assumed
Vaccination
Cost  per  vaccine  dose  (£)  40.00  Scenario  variation  (range  5–40)  Assumed
Cost  of  administration  –  school  (per  dose,  £)  5.60  Gamma (3.92;  1.43)  [31,32]
GP  consultation  cost  (£)  31.00  Normal  (31.00;  16.73)  [33,34]
Nurse  consultation  cost  (£)  6.51  Gamma (4.98;  1.31)  [33,34] h
Adverse  reaction  (anaphylaxis),  hospitalisation  cost  (£)  421.07  Gamma (5.15;  81.79)  [22]
a For the probabilistic cohort model, 1000 simple random samples from the distributions given were run through the model.
b HES data from 1997/98 to 2005/06 were obtained from the University of Bristol (Davidson Ho, emailed personal communication, 18th March 2008); laboratory data for
the  same period from the Health Protection Agency (Mary Ramsay, emailed personal communication, 29th January 2008). In the sensitivity analysis the mean incidence from
1997/98–2005/06 was used. This was manipulated to account for the decline due to MCC  vaccination by estimating the annual number of non-MenC cases and deaths (by
applying serogroup proportions from laboratory conﬁrmed cases to Hospital Episode Statistics admissions) and then adding on MenC cases seen in 2005/06 to each year to
reﬂect current MenC levels.
c National mortality rates and expectations of life by single year of age were obtained from the Ofﬁce for National Statistics Centre for Demography (Nigel Henretty, emailed
personal  communication, 18th December 2009).
d Population ﬁgures by single year of age were obtained from the Ofﬁce for National Statistics Centre for Demography (Megan Elkin, emailed personal communication,
21st  December 2009).
e The proportion of patients with meningococcal disease requiring ambulance transfer to hospital was estimated from the 2003 Meningitis Research Foundation members
survey (Laura Clark, emailed personal communication, 27th July 2011).
f Unpublished data from [24] of the proportion of survivors with major sequelae by age from European studies (Andrew Clark, emailed personal communication, 18th
June  2010).
g The time spent on contact tracing and public health management following a case of meningococcal disease was based on the experience of an Academic Specialty
Registrar in Public Health (Charlotte Chamberlain, emailed personal communication, 18th February 2010).
h For vaccines given concomitantly in primary care, we assumed the appointment with the nurse would be extended by an average of 4 min. Where this was not the case
(infant  vaccination at 6 months of age, and 1–4 year and 16–17 year olds not in full time education as part of catch-up) we assumed the vaccines would be delivered by a
nurse  in a consultation lasting 9 min. These times were based upon the experience of vaccine research nurses (Dianne Web, emailed personal communication, 9th June 2010).
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Fig. 1. Models used to assess the impact of meningococcal vaccination in England. The ‘no vaccination’ model consists of white boxes and solid arrows; the ‘with vaccination’
model  includes shaded boxes and dashed arrows in addition. (A) Cohort model structure: MD,  meningococcal disease. (B) Dynamic model structure: Once individuals are
carriers  they have a chance of developing disease, with the same outcomes as shown in (A) S, susceptible non-vaccinated; M,  infected carrier of a vaccine preventable
meningococcal strain; N, infected carrier of a non-vaccine preventable meningococcal strain; VSI, susceptible vaccinated and immune; VMI, infected carrier of a vaccine
preventable meningococcal strain, vaccinated and immune; VNI, infected carrier of a non-vaccine preventable meningococcal strain, vaccinated and immune; VS, susceptible
vaccinated not immune; VM,  infected carrier of a vaccine preventable meningococcal strain, vaccinated not immune; VN, infected carrier of a non-vaccine preventable
meningococcal strain, vaccinated not immune; m,  force of infection for vaccine preventable meningococcal strains; n, force of infection for non-vaccine preventable
meningococcal strains; , vaccine efﬁcacy against carriage; u, vaccine uptake; w,  waning vaccine protection; b, vaccination booster; i, age; t, time.
using the ratio of the means [40]. Cost-effectiveness acceptability
curves were generated using a net beneﬁt approach.
2.4. Costs and discounting
Three health outcomes were considered: cases averted; deaths
averted; and quality adjusted life years (QALYs) gained. The
cost-effectiveness (utility) analysis was undertaken from the per-
spective of the NHS and personal and social services according
to NICE guidance [41]; the primary outcome was  cost per QALY
gained. Costs were measured in pounds sterling at 2008 prices,
with previous years inﬂated to 2008 levels. All costs and beneﬁts
were assumed to occur at the start of the year with future costs
and beneﬁts discounted according to HM Treasury recommenda-
tions (discount rate of 3.5% for the ﬁrst 30 years, 3.0% in years 31–75
and 2.5% in years 76–99) [42].
3. Results
3.1. Impact of vaccination assuming direct effects only
The model estimates 1799 cases of meningococcal disease (all
capsular groups) could be expected in England over the lifetime of
the 2008 birth cohort, resulting in 18,215 hospital bed days and 91
deaths. An estimated 484 (27%) cases (3756 bed days and 11 deaths)
could be prevented by introducing routine early infant vaccination
(strategy A Tables 2 and 3). Protection begins at 4 months, following
two vaccine doses, and most cases are averted between the ages of
one and two years (Supplementary Fig. 1). Due to waning vaccine
immunity, averted cases decline rapidly after this.
Infants immunised later in childhood experience longer-lasting
immunity, therefore, routine late infant vaccination could result
in more averted cases despite protection starting later in life
(strategy B Tables 2 and 3). Strategies including 12 month boosters
result in more cases averted, compared to those without, because
the duration of protection is assumed to be longer following the
booster. Catch-up strategies result in further case reductions, but
the effects are limited in this model assuming direct protection
only.
Assuming the vaccine costs £40 per dose, early infant vacci-
nation (strategy A) would cost £103·7 million for a single birth
cohort and provide NHS savings of £30·1  million, resulting in a
cost per QALY gained of £162,800. The cost per QALY of a late
infant schedule (strategy B) remains high (£164,100), despite the
greater number of cases avoided, due to the additional cost of call-
ing children for vaccination at 6 months. The vaccine would need
to cost around £9 per dose for these routine infant strategies to
be considered cost-effective (<£30,000 per QALY). Catch-up cam-
paigns are least cost-effective because these involve immunising a
large number of people in ages where disease incidence is relatively
low.
3.2. Impact of vaccination allowing for herd immunity
Routine early infant vaccination with a vaccine that offers 60%
protection against carriage is estimated to prevent more cases
than a strategy allowing for direct protection only (Fig. 2). How-
ever, a considerable disease burden remains because carriage is
low in young children [20] thus the herd immunity effects gener-
ated are limited. Implementing a one-off large-scale catch-up could
reduce the annual number of cases considerably. Ten years after the
implementation of routine infant vaccination with 1–17 year old
catch-up (strategy E), the annual number of cases is estimated to
fall by 71%. Over time, however, cases increase as vaccine immunity
wanes, and the catch-up cohorts age. Routinely vaccinating adoles-
cents could result in a sustained reduction in cases in the long term,
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Table  2
Vaccination strategies modelled.
Routine strategy [months protection]
(Vaccine efﬁcacy %)a
One-off catch-upb [months protection]
(Vaccine efﬁcacy %)a
A Infant: 2,3,4 + 12 months of age [18,36] (75)
B  Infant: 2,4,6 + 12 months of age [24,48] (75)
C  Infant: 2,3,4 months of age [18] (75)
D  Infant: 2,3,4 + 12 months of age [18,36] (75) 1–4 years: 0, 2, 6 [60] (80)
E  Infant: 2,3,4 + 12 months of age [18,36] (75) 1–4 years: 0, 2, 6 [60] (80)
5–17 years: 0, 2 [120] (80)
F  Adolescent: 0, 2, 6 schedule [120] (80)
G  Adolescent: 0, 2, 6 schedule [120] (80) 13–17 years: 0, 2, 6 [120] (80)
Routine infant strategies (A–E) are presented according to the months of age the vaccines are received; adolescent strategies (F, G) are considered in the dynamic model only.
a Numbers in square brackets give the assumed average duration of protection, in months, following the priming and if applicable, booster doses. Numbers in rounded
brackets give the assumed vaccine efﬁcacy against disease.
b Catch-up and adolescent strategies are presented according the spacing of vaccinations in months.
Table 3
Results of the cohort model of meningococcal disease and vaccination in England.
Strategy Undiscounted Discounted
Cases Cases avoided Deaths avoided LYS QALY gained Cost without
vaccination
(£millions)
Cost with
vaccination
(£millions)
Cost per QALY
gained (£)
A 2,3,4 + 12 months 1799 484 11 996 1600 102.9 176.5 162,800
B  2,4,6 + 12 months 1799 496 11 1014 1633 102.9 177.9 164,100
C  2,3,4 months 1799 339 8 696 1119 102.9 159.7 175,600
D  Catch-up in 1–4 year olds 5871 1261 28 2455 4075 323.6 614.3 238,500
E  Catch-up in 1–17 year olds 13,197 2615 74 5648 8836 690.8 1473.1 290,000
Strategies A–C are routine infant vaccination strategies without catch-up; strategies D and E are routine infant vaccination at 2,3,4 + 12 months in addition to the one-off
catch-up presented (please see Table 2 for further details of the strategies modelled). Costs in GBP (£) assuming a vaccine cost per dose of £40 rounded to nearest £100.
but is likely to be more effective in the short term in combination
with catch-up.
Adolescent vaccination either with, or without, catch-up is
the most favourable decision economically (though still above a
£30,000 per QALY threshold at £39,000 and £40,200 respectively,
Table 4). In the base case, this model suggests early routine vacci-
nation (strategy A) could be cost-effective at a willingness to pay of
£30,000 per QALY if the vaccine were to cost £15 per dose. Rou-
tine adolescent vaccination with catch-up (strategy G) could be
cost-effective at £32 per dose.
3.3. Scenario and sensitivity analysis
Results were most sensitive to changes in disease incidence
and case-fatality; with higher incidence and case-fatality, vacci-
nation prevents more cases and deaths and is more economically
favourable (Supplementary Table 2). In the probabilistic analysis
of the cohort model, the results were sensitive to changes in the
parameters with the greatest uncertainty, such as the annual cost
of care for those with sequelae and the quality of life loss for those
individuals (Supplementary Fig. 2).
Fig. 2. Predicted meningococcal cases averted under different vaccination strategies (with herd immunity). Predicted all serogroup meningococcal cases over time under
different vaccination strategies from the dynamic model. Please refere to Table 2 for further details of the vaccination strategies; all runs assume 60% vaccine efﬁcacy against
carriage.
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Table 4
Results of the dynamic model of meningococcal disease and vaccination in England.
Discounted cost per QALY gained (£)
Discounting of costs Base casea 3.5% 5.0% 6.0%
Discounting of beneﬁts 3.5% 5.0% 1.5%
A 2,3,4 + 12 months 96,000 116,200 158,000 £27,900
B  2,4,6 + 12 months 91,800 111,700 153,100 £26,800
D  Routine infant 2,3,4 + 12 months of age plus catch-up in 1–4
year olds (0,2,6 schedule)
97,600 117,700 161,800 £30,700
E  Routine infant 2,3,4 + 12 months of age plus catch-up in 1–4
year olds (0,2,6 schedule) and 5–17 year olds (0,2 schedule)
83,400 97,900 135,000 £30,600
F  Adolescent: 0, 2, 6 schedule 40,200 54,000 84,500 £12,600
G  Routine adolescent (0,2,6 schedule) plus catch-up in 13–17
year olds (0,2,6 schedule)
39,200 51,600 81,100 £13,800
Results from the base case dynamic model showing the effect of varying the discount rates on the cost per Quality Adjusted Life Year; 60% vaccine effectiveness against
carriage, 75% vaccine effectiveness against disease in infants, 80% vaccine effectiveness against disease in catch-up cohorts, £40 per vaccine dose, costs in GBP (£) rounded
to  nearest £100. Please see Table 2 for further details of the strategies modelled.
a 3.5% for the ﬁrst 30 years, 3.0% for years 31–75, 2.5% for years 76 to 100.
More cases and deaths are averted through vaccination when
the carriage prevalence is lowered (Supplementary Fig. 3) and the
discounted cost per QALY is reduced to £69,700 and £86,300 for
routine infant vaccination with (strategy E) and without (strategy
A) large-scale catch-up, respectively. The predicted annual cases
were similar when using a simple preferential population mixing
structure or one using self reported leisure contacts. However, cases
increased more quickly once immunity from large-scale catch-up
had waned, in the model using self reported contacts (Supplemen-
tary Fig. 3). Reducing the proportion of vaccine-preventable strains
from 100% to 75% in the dynamic model resulted in a higher cost
per QALY gained (£131,800) for routine infant vaccination (strat-
egy A). Models were also sensitive to varying vaccine effectiveness,
duration of protection and particularly vaccine cost (Fig. 3 and Sup-
plementary Tables 2 and 3).
The discount rate has a large impact on the cost per QALY gained
(Table 4). None of the strategies considered were cost-effective
at a willingness to pay of £30,000 using Treasury recommended
discount rates (at £40 per vaccine dose). Using differential dis-
counting, with a lower discount rate for health beneﬁts compared
to costs (which allows for increasing value of health beneﬁts), did
result some in strategies appearing cost-effective (assuming a 60%
vaccine efﬁcacy against carriage).
4. Discussion
These are the ﬁrst models to comprehensively assess the poten-
tial impact of introducing vaccines which have the capacity to
protect against capsular group B meningococcal disease in England.
Our results indicate that introducing a ‘MenB’ vaccine, which pro-
vides direct protection only, into the routine infant schedule, could
prevent 27% of meningococcal cases per birth cohort, and that this
could be cost-effective at £9 per vaccine dose. Substantial impact
occurred if the vaccine disrupted carriage as well as preventing
disease. In this scenario, the most efﬁcient programme in the short
term appears to be routine infant vaccination with catch-up, which
after 10 years could reduce annual cases by 71% and be cost-
effective at £17 per dose. Models were sensitive to assumptions
around: disease incidence and case fatality; vaccine cost, duration
of protection and efﬁcacy; quality of life losses from the disease;
and the cost of caring for those with sequelae.
Vaccination with MCC  has shown that the impact of herd immu-
nity effects can be extremely important when predicting the likely
impact and cost-effectiveness of vaccination [43]. We  therefore
used two types of model, including a transmission dynamic model,
in order to appropriately capture potential herd immunity effects
[13]. Unlike previous meningococcal models, our carriage estimates
were drawn from a recent systematic review and meta-analysis
[20] and we assessed the impact of assuming different mixing pat-
terns in the population using simple preferential mixing and mixing
based on self-reported contacts [21]. Our transmission models
differ to others previously used to model meningococcal disease
[43–45] as they are not capsular group speciﬁc. This is not required
as the vaccines in development, unlike their predecessors, do not
target the capsular group. We  chose not to explicitly include N. lac-
tamica as the role of this commensal in affording protection remains
unclear, and if N. lactamica remains at the current level, any protec-
tion is implicitly included through the use of a case: carrier ratio.
That said, our results are consistent with previous models in that a
vaccine able to disrupt carriage can have substantial added beneﬁts
in terms of disease prevention.
There are limited data available to inform some parameters,
in particular relating to the nature of the new vaccines and the
proportion, type and costs associated with sequelae following
meningococcal disease. These results are nevertheless important
because decisions regarding vaccination are starting to be consid-
ered and the scenarios presented cover the most likely features
of the vaccine. We  used hospital admission data from two time
periods to calculate disease incidence. The ability of hospital data
to accurately capture the ‘true’ number of cases in unknown, but
other sources such as laboratory reports are likely to be less com-
plete, and we feel the true incidence probably lies within the range
explored. Assumptions regarding the proportion of survivors with
sequelae come from a recent systematic review of meningococcal
meningitis only [24], so we  may  be underestimating the proportion
of sequelae following meningococcal disease. Sequelae costs were
based on dichotomising individuals into those with mild and severe
sequelae, when in fact there is a considerable range in severity. Pre-
vious models have faced the same paucity of data [43,46] and we
therefore chose to investigate parameter uncertainty in the cohort
model through the use of probabilistic analysis, with particularly
wide distributions for sequelae parameters. We did not consider
possible replacement effects or adverse effects due to the loss of
natural boosting through reduced carriage in the dynamic model
(of meningococci or other nasopharyngeal ﬂora) due to the paucity
of data. The dynamic results here, therefore, may  be optimistic.
There was concern in the UK about the possibility of serogroup
replacement following MCC  introduction, though there is no evi-
dence to suggest that this has occurred [47]. However, serotype
replacement has tempered the impact of the pneumococcal con-
jugate vaccine (introduced in the UK in 2006) [48]. The results
from our models, therefore, should be taken as an indication to the
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Fig. 3. Cost-effectiveness acceptability curves for the cohort model in scenarios analyses. Curves show results under routine infant vaccination (strategy A) of the effect of
varying cost (per dose) of the vaccine, vaccine duration of protection (given in months following the priming and booster doses) and vaccine efﬁcacy (VE).
relative merits of different strategies, particularly as the models
have a long time horizon over which many factors can change,
including strain distributions, disease levels and population
structure.
In the UK, the Joint Committee on Vaccination and Immun-
isation can only recommend the introduction of a vaccine if it
is deemed to be cost-effective [49]. Our models indicate that
a ‘MenB’ vaccine could substantially reduce disease in England,
and be cost-effective if competitively priced. The results are of
relevance, to other countries with similar epidemiology consider-
ing the introduction of one of the new meningococcal vaccines,
though reapplication of our models with country speciﬁc data
may  be desirable in some circumstances (for example, if there are
considerable inter-country differences in vaccine implementation
costs).
Our model results were sensitive to assumptions around the
proﬁle of the vaccine, disease incidence and case fatality and seque-
lae, including quality of life losses and costs of care. Further data
on whether the new vaccines disrupt carriage should be forthcom-
ing, and better information on the duration of protection will also
emerge from the results of ongoing clinical trials [50,51], which
will help to reduce some of the uncertainty in our models. Efforts
are also being made to improve the information surrounding the
impact of the disease in terms of QALY losses and care for those
requiring sequelae [52–54].
5. Conclusion
Using cohort and dynamic models we have shown that a ‘MenB’
vaccine has the capacity to signiﬁcantly reduce meningococcal
disease in England and that vaccine programmes could be cost-
effective if the vaccine is competitively priced.
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